Micrus Endovascular gets approval to market Cerecyte microcoils in Japan

Tweet   

Micrus Endovascular Corporation (Nasdaq:MEND) is 11% higher in today’s pre-market trading after the medical device manufacturer announced earlier in the day it had received approval to market its Cerecyte microcoil product line in Japan. The San Jose, Calif.-based company’s microcoil line is for the endovascular treatment of cerebral aneurysms. Micrus Endovascular said in a statement that the approval will help it expand its market share in Japan, a region it called one of “the fastest-growing markets for embolic coils in the world.”

Before the opening today, shares of Micrus Endovascular are up $1.58 at $16. Shares have ranged from $9.92 to $26 during the past 52 weeks.

For detailed price information and recent news stories on Micrus Endovascular Corporation, click MEND.